Abstract
Dermatomyositis (DM) is an autoimmune disease characterized by muscle involvement of the proximal extremities and specific skin involvement, like Gottron sign and heliotrope rash. Henoch-Schonlein purpura (IgA vasculitis) nephritis is characterized by hematuria and/or proteinuria clinically, with histologic evidence of IgA nephropathy, and also can be clinically characterized by non-thrombocytopenic purpura, presenting with petechiae and ecchymosis on the skin and mucous membranes, often involving multiple organs and systems, accompanied by abdominal pain, joint swelling and pain, and renal lesions. We reported here a patient with symmetric muscle weakness in her proximal limbs and typical Gottron sign, whose laboratory examination showed elevated creatine kinase (CK) level and myogenic damage electromyographically, which were concomitant with dermatomyositis. We applied prednisone combined with cyclophosphamide, and the patient’s muscle strength;, interstitial lung disease and all improved gradually. The patient gradually developed severe hepatic damage [significantly increased glutamic-pyruvic transaminase (ALT), glutamic oxalacetic transaminase (AST) and bilirubin], high fever (body temperature fluctuated between 38.0-39.2 ℃), thrombocytopenia (limb distal purplish rash, some slightly protruded from the skin surface, some fused into a piece, which did not fade with pressure) and intractable diarrhea (water-like stool, antidiarrheal drug treatment was not good), with new onset of the skin lesions on multiple areas of her body, as well as abrupt occurrence of massive proteinuria, which resulted in huge challenges in the following diagnosis and treatment. After extensive differential diagnosis from various directions, including pathological biopsies, it finally came out to be dermatomyositis combined with IgA vasculitis, which had been rarely reported. Both cell-mediated immunity to muscle antigens and immune-complex disease might participate in the pathogenesis. There was evidence that they were immune complex diseases. Several immune mechanisms played an important role in the pathogenesis of both DM and IgA vasculitis. We conducted a substantial literature review of the above diseases. The purpose of our study is to strengthen the clinical understanding of such complicated diseases, and to highlight the importance of pathological biopsy in the diagnosis (renal biopsy pathology gave us a definite diagnosis). And what is more important is that seizing the opportunity to initiate treatment can control the disease and improve the prognosis.
Keywords: Dermatomyositis, IgA vasculitis, Henoch-Schonlein purpura, Renal damage, Pathology
1. 病例资料
患者女性,63岁,主因“眶周水肿性红斑2周,四肢肌痛、无力伴咳嗽和吞咽困难1周”于2017年12月14日收住北京大学国际医院风湿免疫科。
入院体格检查:双眼眶周呈明显水肿性紫红斑,双手指间关节伸侧有紫红色充血疹,甲周可见红斑和瘀点,手指掌面皮肤皲裂、角化,双肺呼吸音粗,可闻及散在湿啰音,四肢肌肉有压痛,近端肌力3级,远端肌力5级,其余查体无异常。
实验室检查:谷丙转氨酶83 U/L,谷草转氨酶266 U/L,肌酸激酶6 649 U/L,肌酸激酶同工酶(化学法)111 U/L,乳酸脱氢酶584 U/L;肌炎谱示anti-SAE抗体阳性,抗核抗体1 :160斑点型,抗dsDNA阴性,抗ENA谱均为阴性;补体C3 1.66 g/L(0.90~1.80 g/L),补体C4 0.21 g/L(0.10~0.40 g/L)。胸部CT示双侧胸膜下和肺内多发实变和浸润影(图1A、B)。支气管镜检查提示支气管黏膜急性炎症改变,灌洗液化验有大量吞噬细胞和纤毛柱状上皮细胞,未见癌细胞。肌电图提示肌源性损害。初步诊断为皮肌炎合并机化性肺炎,给予甲泼尼龙80 mg、每日1次,联合环磷酰胺400 mg、每两周1次,静脉输注治疗。2周后患者皮疹明显消退,复查谷丙转氨酶、谷草转氨酶、肌酸激酶、乳酸脱氢酶基本降至正常,但近端肌力改善不明显。环磷酰胺于静脉输注2次后改为每日50 mg口服。环磷酰胺口服约1个月时患者开始出现进行性加重的黄疸和全身皮肤瘙痒,复查血常规正常,血谷丙转氨酶1 612 U/L、谷草转氨酶1 042 U/L、碱性磷酸酶245 U/L、转肽酶494 U/L、总胆红素298.9 μmol/L、直接胆红素224.4 μmol/L。考虑诊断为环磷酰胺所致药物性肝损害伴胆道梗阻。于2018年3月2日停用环磷酰胺,给予患者保肝、退黄治疗1个半月,患者黄疸逐渐好转,于2018年4月16日复查肝酶和胆管酶指标均恢复正常。
1.
患者入院时胸部CT可见双侧胸膜下和肺内多发片状实变和浸润影(A、B),3个月后复查胸部CT见双肺间质病变较前减轻,但出现少量胸水、腹水和心包积液(C)
Multiple subpleural and intrapulmonary patches of consolidation and infiltration were observed on chest CT scan on admission (A and B), chest CT reexamination 3 months later showed that the interstitial lesions of both lungs were less than before, but a small amount of hydrothorax, ascites and pericardial effusion were present (C)
在上述治疗期间,患者于2018年3月19日(此时因转氨酶升高已停用环磷酰胺,保留泼尼松30 mg、每日1次口服)开始出现间断发热,体温波动于38.0~39.2 ℃,伴纳差和下肢逐渐加重的可凹性水肿,继而反复出现水样腹泻(每日2~4次),并在一次进食牛奶后明显加重(每日多达6~10次),无黏液脓血便和腹痛,化验血白蛋白呈进行性下降趋势,相距2周先后2次复查胸腹CT提示双肺间质病变较前减轻,但出现少量胸水、腹水和心包积液(图1C)。在调整肠道菌群的基础上先后给予厄他培南和磷酸奥司他韦(商品名:达菲)治疗各1周,上述症状无改善,后改用亚胺培南西司他丁钠(商品名:泰能)抗感染治疗后热退,但腹泻和下肢水肿持续存在。患者发热约2周后于2018年3月30日(此时已停用环磷酰胺2月余)开始反复出现四肢远端紫红色点状皮疹,部分稍突出于皮面,部分融合成片,压之不褪色(图2),伴口唇黏膜水肿性红斑、糜烂、破溃、结痂和出血(图3)。维持前述治疗1个月左右患者皮疹有所减轻,期间于左手背皮疹处行组织病理活检,结果提示真皮血管周围有大量淋巴细胞浸润。病程中患者水肿进一步加重,从下肢蔓延至腹部、胸部和颜面部,伴明显睑结膜水肿,于2018年4月3日行正电子发射型计算机断层显像(positron emission computed tomography,PET-CT)检查,未见肿瘤征象,亦无其他重要发现。
2.
在诊治过程中新出现的下肢皮疹
New lower limb rash during the diagnosis and treatment
3.

在诊治过程中新出现的口唇黏膜皮疹(已部分愈合)
New oral mucosa rash (partially healed) during the diagnosis and treatment
从2018年4月20日开始,患者的实验室检查出现尿蛋白+++、尿潜血++、24 h尿蛋白定量6.52 g、血清尿素10.06 mmol/L、肌酐122 μmol/L、白蛋白 24 g/L。进一步化验提示IgA 6.38 g/L、补体C3 0.36 g/L、抗核抗体1 :160(斑点型)、抗双链DNA阴性。于2018年4月27日行肠镜检查,提示回盲瓣溃疡伴升结肠糜烂(图4),一周后肠镜病理结果提示回盲瓣肠黏膜组织糜烂,固有层淋巴细胞、浆细胞及少许中性粒细胞浸润,未见隐窝炎及隐窝脓肿。从2018年5月8日开始给予患者甲泼尼龙200 mg、静脉输注1 d,续500 mg、每日1次、连续3天,后调整为醋酸泼尼松50 mg、每日1次口服,并加用环孢素A 50 mg、每日2次,2周后患者皮疹和腹泻好转,近端肌力3+级。复查24 h尿蛋白定量增至11.18 g,同时出现血小板下降(58×109/L),给予人免疫球蛋白静脉输注20 g×3 d,待血小板升至80×109/L,于2018年6月1日行肾脏穿刺活检,病理检查提示系膜增生性肾小球肾炎伴急性肾小管损伤(图5),荧光染色提示IgA和IgM于系膜区呈颗粒样沉积,结合电子显微镜检查结果,符合IgA肾病。临床最后诊断:皮肌炎合并环磷酰胺肝损害和IgA血管炎(肠道和肾损害)。继续给予患者激素联合环孢素治疗,2个月后复查24 h尿蛋白降至3.28 g,环孢素治疗约半年时患者近端肌力4级,尿蛋白降至0.74 g/24 h,在此过程中,血清肌酐和尿素水平呈逐渐上升的趋势,最高时肌酐180 μmol/L、尿素25.86 mol/L,考虑为环孢素A肾毒性,为此将之改为吗替麦考酚酯分散片500 mg、每日2次。最近半年患者尿蛋白已转阴性,血清肌酐和尿素已降至接近正常水平。
4.
纤维内镜见回盲瓣有一处0.8 cm×1.0 cm大小溃疡,上覆薄白苔(A,箭头所示);升结肠黏膜血管纹理模糊,可见广泛点状或颗粒状糜烂(B)
Fibroendoscopy showed a 0.8 cm×1.0 cm ulcer in the ileocecal valve covered with thin white moss (A, the arrow shows); the vascular texture of the mucosa of the ascending colon is blurred, and extensive punctate or granular erosion can be seen (B)
5.
患者的肾脏病理检查示肾小球系膜细胞和基质轻至中度弥漫增生(A,PAS染色 ×400);肾小管上皮细胞空泡变性,小灶状萎缩,可见红细胞(箭头)和蛋白管型(*号)(B,HE染色 ×400)
Renal pathologic examination showed mild to moderate diffuse hyperplasia of mesangial cells and stroma (A, PAS staining ×400); vacuolar degeneration and focal atrophy of renal tubule epithelial cells, red blood cells (arrow) and protein tubule type (*) (B, HE staining ×400)
2. 分析与讨论
患者为63岁女性,主要表现为四肢近端肌无力伴吞咽困难、向阳性皮疹及Gottron征,化验肌酸激酶增高,肌电图提示为肌源性受损,可以确定皮肌炎的诊断。经过大剂量激素和免疫抑制剂治疗,患者皮疹和肌酶水平迅速改善,但肌力改善不明显,此外,伴随着黄疸,患者出现了一系列令人意想不到的病情变化。为了便于阐述,我们将其总结为以下几个方面。
第一,患者接受泼尼松联合环磷酰胺治疗,皮疹较快获得缓解,肌酶也迅速下降,但出现了进行性加重的黄疸伴转氨酶及胆红素显著升高。考虑首先原因可能为环磷酰胺所致肝损伤,环磷酰胺经肝细胞色素P450酶系代谢生成丙烯醛、4-羟化物和氯乙醛,这些代谢产物可导致细胞膜脂质过氧化,引发氧化应激损伤[1],一方面引起肝细胞溶解破坏,大量释放转氨酶,另一方面损伤波及肝内胆管系统,造成胆道梗阻,引起严重的黄疸。其次,需明确有无合并肿瘤,皮肌炎患者中肿瘤的发病率显著高于其他自身免疫病患者及普通人群,其发病率可达12%~16%,经过磁共振胰胆管成像及PET-CT检查,均未发现肿瘤证据,肿瘤可能性可以排除。此外,还需要明确有无急性黄疸型肝炎,经检查丙型病毒性肝炎抗体、丙型肝炎病毒-RNA、乙型病毒性肝炎五项、甲型病毒性肝炎抗体、戊型病毒性肝炎抗体均未见异常,可除外病毒性肝炎诊断。停用环磷酰胺后,予以保肝、退黄治疗1月余后转氨酶及胆红素逐渐降至正常,支持环磷酰胺所致急性肝损伤。
第二,在治疗环磷酰胺药物性肝损害的过程中,患者开始出现反复发热、下肢水肿、顽固性腹泻和血清白蛋白水平进行性下降。患者的发热原因可能是:一方面,患者在使用大剂量糖皮质激素和环磷酰胺治疗后出现发热,要考虑因机体免疫力下降而引起感染的可能性;另一方面,皮肌炎本身导致的非感染性发热。虽然在诊治过程中没有发现明确的感染灶,也没有病原学的证据,但是经过足量和足疗程的抗感染治疗后,患者发热最终得到控制,同时考虑到患者发热过程中一直有中等剂量以上的激素治疗,因此在感染性和非感染性发热之间,考虑前者的可能性大。
下肢水肿和腹泻可能另有原因。明显的低蛋白血症(肾性、营养不良或肠道吸收障碍或者丢失)、心功能不全、下肢血栓形成或者淋巴回流受阻是引起下肢水肿的常见原因,少数情况下包括皮肤血管炎、系统性硬化症、皮肌炎急性期或者嗜酸性筋膜炎也可出现下肢水肿。不同病因导致的水肿其体征各有特点,本例患者后期出现的水肿为明显可凹性,因此低蛋白血症所致可能性最大,而上述其他原因则需要进一步鉴别。
对于顽固性水样腹泻,需要考虑多种因素所致,包括:(1)皮肌炎消化道受累:患者肠镜示回盲瓣溃疡、升结肠糜烂,结合患者症状、镜下表现不除外此种可能性;(2)肠道感染:患者年龄较大,既往长期使用激素及免疫抑制剂,需要考虑免疫功能下降后合并肠道感染的可能;(3)肠道菌紊乱:患者因高热而接受泰能、头孢哌酮钠舒巴坦钠(商品名:舒普深)等抗生素抗感染治疗,便涂片球菌、杆菌比例(球杆比)检查结果为10 :1,同时难辨梭菌抗体阴性,考虑存在肠道菌群紊乱的可能性;(4)皮肌炎合并消化道肿瘤:PET-CT及胃肠镜检查已排除此种可能。
第三,下肢水肿和腹泻尚未缓解,患者全身多处又出现多种新发皮疹,包括口唇水肿性红斑与不易愈合的溃疡、糜烂、结痂和出血,以及下肢的可触性紫癜。可触性紫癜多见于皮肤小血管炎,包括过敏性紫癜、高球蛋白血症、抗中性粒细胞胞浆抗体(antineutrophil cytoplasmic antibodies,ANCA)相关性血管炎、低补体血症性血管炎或者某些感染等。口唇黏膜的多形性病变需要考虑非特异性阿弗他溃疡,全身性疾病如白塞病、系统性红斑狼疮、ANCA相关性血管炎、炎性肠病等,也要考虑细胞毒性药物(如甲氨蝶呤、环磷酰胺等)所致。如此多变的皮损,为明确诊断行皮肤活检,结果提示真皮弹力纤维变性,血管周围及间质内有大量淋巴细胞浸润,表明患者存在皮肤血管炎。
第四,患者初始起病时并无肾脏受累,但其水肿仍在加重并向肢体近心端蔓延,此时突然出现大量蛋白尿和镜下血尿,24 h尿蛋白定量最高达11.18 g,其他化验结果包括抗核抗体阳性、补体C3减低、血清肌酐和尿素水平轻度升高,因此考虑存在系统性红斑狼疮的可能性,在给予大剂量激素冲击治疗和环孢素治疗的基础上尿蛋白无好转,为此行肾穿刺病理活检,结果意外发现肾脏病理为IgA肾病伴急性肾小管损伤,这一结果排除了狼疮肾炎的诊断。
IgA肾病和过敏性紫癜性肾炎有着十分相似的肾脏病理表现,两者的区别在于临床上后者存在可触性紫癜皮疹,其病理典型表现为具有IgA沉积的白细胞破碎性血管炎,因此,过敏性紫癜也称为IgA血管炎。除了可触性紫癜外,IgA血管炎的皮肤损害也可表现为瘀斑、水泡,甚至因血管炎而导致局部缺血、坏死和结痂,在皮肤血管炎的急性期也可伴发明显水肿。本例患者下肢存在可触性紫癜,其躯干和口唇的皮疹也符合IgA血管炎的其他皮肤损害,结合其典型的IgA肾病的病理表现,可以诊断为过敏性紫癜性肾炎或者IgA血管炎合并肾脏损害,在其发生肾脏损害之前出现的水肿,不除外为血管炎所致。过敏性紫癜多见于儿童,成人较少发生,成人过敏性紫癜累及肾脏时更容易出现肾病综合征,甚至形成新月体,并发展成终末期肾病[2,3]。本例患者在紫癜性皮疹出现后不久便出现大量蛋白尿和镜下血尿,伴肾功能下降,如果治疗不及时,也极有可能发展成终末期肾病。
关于IgA血管炎中补体的减低已有不少文献述及[4,5,6,7,8,9],最近国内苏州大学儿童医院发表的跟踪报告提示,在其随访的3 765例儿童过敏性紫癜患者中,有265例出现了低补体血症,在平均3.8年的随访过程中,没有加1例发展成系统性红斑狼疮[5]。
IgA血管炎的消化道受累可有多种表现,可出现腹痛、腹泻,也可出现恶心、呕吐,或者慢性消化不良[10]。纤维内镜下肠道黏膜可出现类似皮肤紫癜样的表现,也可出现溃疡、糜烂[11],甚至发生肠套叠或肠穿孔[12,13]。也有少数严重的腹泻患者被证实为蛋白丢失性肠病[14]。组织病理检查可出现十二指肠炎、空回肠及结肠的非特异性炎症,也可出现白细胞破碎性血管炎[15,16,17]。由此可见,本例患者出现的顽固性腹泻伴严重的低蛋白血症,后来发现回盲部的溃疡以及升结肠部位的糜烂除了前面所述原因外,也可能与IgA血管炎相关。
皮肌炎与IgA血管炎有什么内在联系吗?以往文献中皮肌炎合并IgA血管炎的相关报道非常罕见。IgA肾病和IgA血管炎的起病诱因、发病年龄、临床表现多有一致或重叠,二者在发病机制上也有一定共性。正是因此,了解IgA肾病与皮肌炎之间的关系也许能获得一些启发。Yen等[18]报道了皮肌炎合并IgA肾病的病例,认为IgA肾病可能与皮肌炎存在某些共同的免疫病理基础。循环中免疫复合物在肾脏内沉积,激活补体系统可引起肾小球肾炎或急性间质性肾炎。近来的研究认为,皮肌炎的肾损害可能被低估了,其发生率可达到20.5%~23.3%[18,19,20],可见皮肌炎肾损害也许并非以往所认为的那么罕见,但由于肾脏穿刺病理活检的局限性,该类患者进行肾穿刺的相对较少,现有报道的病理类型主要包括局灶节段性肾小球硬化、系膜增生性肾小球肾炎、轻微肾小球病变及IgA肾病等。
通过本例患者的诊治我们认为,皮肌炎可以与IgA血管炎合并存在,合理应用糖皮质激素联合环孢素A[21]或者吗替麦考酚酯等免疫抑制剂均有利于皮肌炎及其合并的IgA血管炎和肾脏损害的控制,并使肾功能得到恢复。
(志谢:诚挚感谢北京大学第一医院肾内科、卫生部肾脏疾病重点实验室王素霞教授和喻小娟医师为本文提供肾脏病理的图片和会诊意见。)
References
- 1.Russo RAG, Katsicas MM, Dávila M, et al. Cholestasis in juve-nile dermatomyositis: report of three cases. Arthritis Rheum. 2001;44(5):1139–1142. doi: 10.1002/1529-0131(200105)44:5<1139::AID-ANR195>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
- 2.Ueda H, Miyazaki Y, Tsuboi N, et al. Clinical and pathological characteristics of elderly Japanese patients with IgA Vasculitis with nephritis: a case series. Intern Med. 2019;58(1):31–38. doi: 10.2169/internalmedicine.1379-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Tan J, Tang Y, Xu Y, et al. The clinicopathological characteristics of Henoch-Schonlein purpura nephritis with presentation of nephrotic syndrome. Kidney Blood Press Res. 2019;44(4):754–764. doi: 10.1159/000501459. [DOI] [PubMed] [Google Scholar]
- 4.Chua JS, Zandbergen M, Wolterbeek R, et al. Complement-mediated microangiopathy in IgA nephropathy and IgA vasculitis with nephritis. Mod Pathol. 2019;32(8):1147–1157. doi: 10.1038/s41379-019-0259-z. [DOI] [PubMed] [Google Scholar]
- 5.Lin Q, Li X. Children with Henoch-Schonlein purpura with low complement levels: follow-up for >6 years. Pediatr Nephrol. 2017;32(7):1279. doi: 10.1007/s00467-017-3630-7. [DOI] [PubMed] [Google Scholar]
- 6.Yu JH, Lee KB, Lee JE, et al. A case of elderly-onset crescentic Henoch-Schonlein purpura nephritis with hypocomplementemia and positive MPO-ANCA. J Korean Med Sci. 2012;27(8):957–960. doi: 10.3346/jkms.2012.27.8.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Lin Q, Min Y, Li Y, et al. Henoch-Schonlein purpura with hypocomplementemia. Pediatr Nephrol. 2012;27(5):801–806. doi: 10.1007/s00467-011-2070-z. [DOI] [PubMed] [Google Scholar]
- 8.Motoyama O, Iitaka K. Henoch-Schonlein purpura with hypocomplementemia in children. Pediatr Int. 2005;47(1):39–42. doi: 10.1111/j.1442-200x.2005.02005.x. [DOI] [PubMed] [Google Scholar]
- 9.Garcia-Fuentes M, Martin A, Chantler C, et al. Serum complement components in Henoch-Schonlein purpura. Arch Dis Child. 1978;53(5):417–419. doi: 10.1136/adc.53.5.417. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Zhang Y, Huang X. Gastrointestinal involvement in Henoch-Schonlein purpura. Scand J Gastroenterol. 2008;43(9):1038–1043. doi: 10.1080/00365520802101861. [DOI] [PubMed] [Google Scholar]
- 11.Sasaki K, Nukuda Y, Masuda T, et al. Endoscopically and histologically documented gastrointestinal lesions in an adult patient with Henoch-Schonlein purpura. Endoscopy. 1994;26(7):629–630. doi: 10.1055/s-2007-1009054. [DOI] [PubMed] [Google Scholar]
- 12.Basu R. Perforation of the bowel in Henoch-Schonlein purpura. Arch Dis Child. 1959;34:342–343. doi: 10.1136/adc.34.176.342. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Emanuel B, Lieberman AD, Rosen S. Intussusception due to Henoch-Schonlein purpura. Case reports and review of the literature. Ill Med J. 1962;122:162–167. [PubMed] [Google Scholar]
- 14.Nakamura A, Fuchigami T, Inamo Y. Protein-losing enteropathy associated with Henoch-Schonlein purpura. Pediatr Rep. 2010;2(2):e20. doi: 10.4081/pr.2010.e20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Louie CY, Gomez AJ, Sibley RK, et al. Histologic features of gastrointestinal tract biopsies in IgA vasculitis (Henoch-Schonlein purpura) Am J Surg Pathol. 2018;42(4):529–533. doi: 10.1097/PAS.0000000000001036. [DOI] [PubMed] [Google Scholar]
- 16.Han Y, Jin SY, Kim DW, et al. Endoscopic and microscopic findings of gastrointestinal tract in Henoch-Schonlein purpura: Single institute experience with review of literature. Medicine (Baltimore) 2019;98(20):e15643. doi: 10.1097/MD.0000000000015643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Akkari I, Mrabet S, Ben Jazia E. Gastrointestinal biopsy in Henoch-Schonlein purpura: A great diagnostic contribution. Eur J Case Rep Intern Med. 2017;4(9):000662. doi: 10.12890/2017_000662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yen T, Huang J, Chen C. Unexpected IgA nephropathy during the treatment of a young woman with idiopathic dermatomyositis: case report and review of the literature. J Nephrol. 2003;16(1):148–153. [PubMed] [Google Scholar]
- 19.舒 晓明, 卢 昕, 王 国春. 中国人多发性肌炎/皮肌炎合并肾脏损害的临床特点(附文献复习) 中日友好医院学报. 2017;31(2):67–70. [Google Scholar]
- 20.钱 莹, 任 红, 陈 晓农, et al. 多发性肌炎和皮肌炎的肾脏损害分析. 上海交通大学学报(医学版) 2011;31(4):451–454. doi: 10.3969/j.issn.1674-8115.2011.04.015. [DOI] [Google Scholar]
- 21.Georgaki-Angelaki E, Kostaridou S, Lourida A, et al. Abrupt and durable remission of Henoch-Schonlein purpura nephritis with cyclosporine A. NDT Plus. 2008;1(5):300–302. doi: 10.1093/ndtplus/sfn105. [DOI] [PMC free article] [PubMed] [Google Scholar]




